Peptidomimetic therapeutics: scientific approaches and opportunities

Banting, 1922, Pancreatic extracts in the treatment of diabetes mellitus, Can. Med. Assoc. J., 12, 141

White, 2011, Contemporary strategies for peptide macrocyclization, Nat. Chem., 3, 509, 10.1038/nchem.1062

Craik, 2013, The future of peptide-based drugs, Chem. Biol. Drug Des., 81, 136, 10.1111/cbdd.12055

Uhlig, 2014, The emergence of peptides in the pharmaceutical business: from exploration to exploitation, EuPA Open Proteom., 4, 58, 10.1016/j.euprot.2014.05.003

Fosgerau, 2015, Peptide therapeutics: current status and future directions, Drug Discov. Today, 20, 122, 10.1016/j.drudis.2014.10.003

Sachdeva, 2016, Peptides as ‘drugs’: the journey so far, Int. J. Pept. Res. Ther., 1

Otvos, 2014, Current challenges in peptide-based drug discovery, Front. Chem., 2, 62, 10.3389/fchem.2014.00062

Bock, 2013, Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraints, ACS Chem. Biol., 8, 488, 10.1021/cb300515u

Kaspar, 2013, Future directions for peptide therapeutics development, Drug Discov. Today, 18, 807, 10.1016/j.drudis.2013.05.011

Anthony, 2009, From somatostatin to octreotide LAR: evolution of a somatostatin analogue, Curr. Med. Res. Opin., 25, 2989, 10.1185/03007990903328959

Ovadia, 2010, Improvement of drug-like properties of peptides: the somatostatin paradigm, Expert Opin. Drug Discov., 5, 655, 10.1517/17460441.2010.493935

Ferro, 2004, Intracellullar peptides as putative natural regulators of protein interactions, J. Neurochem., 91, 769, 10.1111/j.1471-4159.2004.02757.x

Amiram, 2013, Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control, Proc. Natl. Acad. Sci. U. S. A., 110, 2792, 10.1073/pnas.1214518110

Gentilucci, 2010, Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization, Curr. Pharm. Des., 16, 3185, 10.2174/138161210793292555

Stoop, 2015, New opportunities in vasopressin and oxytocin research: a perspective from the amygdala, Annu. Rev. Neurosci., 38, 369, 10.1146/annurev-neuro-071714-033904

Ozgonenel, 2007, How do you treat bleeding disorders with desmopressin?, Postgrad. Med. J., 83, 159, 10.1136/pgmj.2006.052118

Gonzalez-Ruiz, 2016, Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections, Infect. Drug Resist., 9, 47

Kim, 2016, Afamelanotide: a review in erythropoietic protoporphyria, Am. J. Clin. Dermatol., 17, 179, 10.1007/s40257-016-0184-6

Grunewald, 2009, Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids, Proc. Natl. Acad. Sci. U. S. A., 106, 4337, 10.1073/pnas.0900507106

Roxin, 2012, Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides, Future Med. Chem., 4, 1601, 10.4155/fmc.12.75

Furman, 2014, A genetically encoded aza-Michael acceptor for covalent cross-linking of protein-receptor complexes, J. Am. Chem. Soc., 136, 8411, 10.1021/ja502851h

Hallam, 2015, Antibody conjugates with unnatural amino acids, Mol. Pharm., 12, 1848, 10.1021/acs.molpharmaceut.5b00082

Galan, 2016, Library-based display technologies: where do we stand?, Mol. Biosyst., 12, 2342, 10.1039/C6MB00219F

Gietz, 2006, Yeast two-hybrid system screening, Methods Mol. Biol., 313, 345

Kessler, 1982, Peptide conformations 19. Conformation and biological-activity of cyclic-peptides, Angew. Chem. Int. Ed. Engl., 21, 512, 10.1002/anie.198205121

Chatterjee, 2013, N-methylation of peptides and proteins: an important element for modulating biological functions, Angew. Chem. Int. Ed. Engl., 52, 254, 10.1002/anie.201205674

Khoury, 2014, Forcefield_NCAA: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family, ACS Synth. Biol., 3, 855, 10.1021/sb400168u

Gavras, 2001, Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure, Hypertension, 37, 342, 10.1161/01.HYP.37.2.342

Zuraw, 2010, HAE therapies: past present and future, Allergy Asthma Clin. Immunol., 6, 23, 10.1186/1710-1492-6-23

Bork, 2008, Icatibant, Nat. Rev. Drug Discov., 7, 801, 10.1038/nrd2694

Gruber, 2012, Exploring bioactive peptides from natural sources for oxytocin and vasopressin drug discovery, Future Med. Chem., 4, 1791, 10.4155/fmc.12.108

Whitby, 2011, Design, synthesis, and validation of a beta-turn mimetic library targeting protein-protein and peptide-receptor interactions, J. Am. Chem. Soc., 133, 10184, 10.1021/ja201878v

Ruiz-Gomez, 2010, Update 1 of: over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure, Chem. Rev., 110, PR1, 10.1021/cr900344w

Becker, 1999, Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library, J. Biol. Chem., 274, 27513, 10.1074/jbc.274.39.27513

Gilon, 1991, Backbone cyclization – a new method for conferring conformational constraint on peptides, Biopolymers, 31, 745, 10.1002/bip.360310619

Schafmeister, 2000, An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides, J. Am. Chem. Soc., 122, 5891, 10.1021/ja000563a

Dawson, 1994, Synthesis of proteins by native chemical ligation, Science, 266, 776, 10.1126/science.7973629

Moore, 2012, Knottins: disulfide-bonded therapeutic and diagnostic peptides, Drug Discov. Today Technol., 9, e1, 10.1016/j.ddtec.2011.07.003

Saab, 2012, Bleeding risk and safety profile related to the use of eptifibatide: a current review, Expert Opin. Drug Saf., 11, 315, 10.1517/14740338.2012.650164

Survase, 2011, Cyclosporin A: a review on fermentative production, downstream processing and pharmacological applications, Biotechnol. Adv., 29, 418, 10.1016/j.biotechadv.2011.03.004

Love, 2014, Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome, Am. J. Health Syst. Pharm., 71, 1081, 10.2146/ajhp130575

Jones, 2007, Therapies for diabetes: pramlintide and exenatide, Am. Fam. Physician, 75, 1831

Pope, 2013, Ziconotide: a clinical update and pharmacologic review, Expert Opin. Pharmacother., 14, 957, 10.1517/14656566.2013.784269

Tan, 2016, Stapled peptide design: principles and roles of computation, Drug Discov. Today, 10.1016/j.drudis.2016.06.012

Walensky, 2014, Hydrocarbon-stapled peptides: principles, practice, and progress, J. Med. Chem., 57, 6275, 10.1021/jm4011675

Lonn, 2015, Cationic PTD/CPP-mediated macromolecular delivery: charging into the cell, Expert Opin. Drug Deliv., 12, 1627, 10.1517/17425247.2015.1046431

Madsbad, 2009, Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results, Best Pract. Res. Clin. Endocrinol. Metab., 23, 463, 10.1016/j.beem.2009.03.008

Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, Diabetes Care, 30, 1487, 10.2337/dc06-2375

Veuillez, 2001, Factors and strategies for improving buccal absorption of peptides, Eur. J. Pharm. Biopharm., 51, 93, 10.1016/S0939-6411(00)00144-2

Morishita, 2006, Is the oral route possible for peptide and protein drug delivery?, Drug Discov. Today, 11, 905, 10.1016/j.drudis.2006.08.005

Prausnitz, 2004, Current status and future potential of transdermal drug delivery, Nat. Rev. Drug Discov., 3, 115, 10.1038/nrd1304

von Lueder, 2015, New medical therapies for heart failure, Nat. Rev. Cardiol., 12, 730, 10.1038/nrcardio.2015.137

Mas-Moruno, 2010, Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation, Anticancer Agents Med. Chem., 10, 753, 10.2174/187152010794728639

Becker, 2015, Metabolism and disposition of the alphav-integrin b3/b5 receptor antagonist cilengitide, a cyclic polypeptide, in humans, J. Clin. Pharmacol., 55, 815, 10.1002/jcph.482

Gilbert, 2012, Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery, J. Neurooncol., 106, 147, 10.1007/s11060-011-0650-1

Khasraw, 2016, Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial, J. Neurooncol., 128, 163, 10.1007/s11060-016-2094-0

Zhao, 2004, Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury, J. Biol. Chem., 279, 34682, 10.1074/jbc.M402999200

Szeto, 2008, Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury, Antioxid. Redox Signal., 10, 601, 10.1089/ars.2007.1892

Chen, 2011, Mitochondria-targeted peptide MTP-131 alleviates mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells, Investig. Ophthalmol. Vis. Sci., 52, 7027, 10.1167/iovs.11-7524

Li, 2011, Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells, Biochem. Biophys. Res. Commun., 404, 349, 10.1016/j.bbrc.2010.11.122